Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2007
05/29/2007CA2197673C Drugs to improve synaptic transmission
05/29/2007CA2190659C Taxoids, preparation and pharmaceutical compositions containing them
05/29/2007CA2173317C Pharmaceutically acceptable polymeric tissue coating
05/29/2007CA2168080C Process for the preparation of 1-(2'-deoxy-2',2'-difluoro- d-ribopentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro- beta-d-ribo-pentopyranose
05/29/2007CA2090612C Method of reversing local anesthesia and reagent system therefor
05/24/2007WO2007059515A2 Compositions of lipoxygenase inhibitors
05/24/2007WO2007059500A2 Novel process and formulations
05/24/2007WO2007059482A2 Modulation of immune responses
05/24/2007WO2007059445A2 Synergistic combinations of norketamine and opioid analgesics
05/24/2007WO2007059435A2 Compositions and methods for enhancing cognitive function
05/24/2007WO2007059431A1 Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
05/24/2007WO2007059422A2 Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and method of making same
05/24/2007WO2007059421A2 Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
05/24/2007WO2007059356A2 Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
05/24/2007WO2007059330A2 Cubane nucleoside analogs
05/24/2007WO2007059329A2 Methods and compositions for treating cancer
05/24/2007WO2007059323A2 Certain chemical entities, compositions, and methods
05/24/2007WO2007059311A2 Furoxan compounds, compositions and methods of use
05/24/2007WO2007059299A1 Aminopyrimidines useful as kinase inhibitors
05/24/2007WO2007059296A2 Ligands for mineralocorticoid receptor (mr) and methods for screening for or designing mr ligands
05/24/2007WO2007059242A1 Low-density lipoprotein receptor-related protein 2 clears amyloid-beta peptide a cross the blood-brian barrier via apolipoprotein j
05/24/2007WO2007059229A1 Hiv integrase inhibitors
05/24/2007WO2007059226A2 Photoactivatable antimicrobial agents
05/24/2007WO2007059219A1 Azaindazoles useful as inhibitors of kinases
05/24/2007WO2007059195A1 Integrin-binding small molecules
05/24/2007WO2007059188A1 Method for treating joint damage
05/24/2007WO2007059157A1 Bisamide inhibitors of hedgehog signaling
05/24/2007WO2007059155A1 Treatment of cancers having resistance to chemotherapeutic agents
05/24/2007WO2007059154A2 Treatment of cancers with acquired resistance to kit inhibitors
05/24/2007WO2007059145A2 Process for metabolic control and high solute clearance and solutions for use therein
05/24/2007WO2007059125A2 Hiv integrase inhibitors
05/24/2007WO2007059118A1 Combretastatin derivatives and related therapeutic methods
05/24/2007WO2007059113A2 Certain chemical entities, compositions, and methods
05/24/2007WO2007059111A2 Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
05/24/2007WO2007059108A2 Substituted quinolones and methods of use
05/24/2007WO2007059106A2 Administration of mntor inhibitor to treat patients with cancer
05/24/2007WO2007059099A2 Boroproline combination therapy for cancer
05/24/2007WO2007059078A1 Treatment of multiple myeloma with dasatinib
05/24/2007WO2007059047A2 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
05/24/2007WO2007059041A2 Combinations and methods of using an immunomodulatory oligodeoxynucleotide
05/24/2007WO2007059039A1 Thyroxine derivatives for preconditioning against stroke
05/24/2007WO2007059021A1 Soft anticholinergic zwitterions
05/24/2007WO2007059019A2 Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts
05/24/2007WO2007059008A2 N-substituted indenoisoquinolines and syntheses thereof
05/24/2007WO2007058995A1 Manually actuated contactless card
05/24/2007WO2007058992A2 Mutations and polymorphisms of hdac6
05/24/2007WO2007058991A2 Mutations and polymorphisms of c-abl
05/24/2007WO2007058990A2 Therapy using cytokine inhibitors
05/24/2007WO2007058960A1 Sulfamoyl benzamides as cannabinoid receptor modulators
05/24/2007WO2007058935A2 Ophthalmic composition for dry eye therapy
05/24/2007WO2007058927A1 Histone deacetylase inhibitors as therapeutics for neurological diseases
05/24/2007WO2007058894A2 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
05/24/2007WO2007058862A2 Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
05/24/2007WO2007058852A2 Inhibitors of akt activity
05/24/2007WO2007058850A2 Inhibitors of akt activity
05/24/2007WO2007058805A2 Compositions and methods for treating cns disorders
05/24/2007WO2007058801A1 Pharmaceutical compositions for the administration of aptamers
05/24/2007WO2007058800A2 Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same
05/24/2007WO2007058664A1 Atorvastatin formulation
05/24/2007WO2007058663A2 Recombinant bcg strains with enhanced ability to escape the endosome
05/24/2007WO2007058646A1 Hiv integrase inhibitors: cyclic pyrimidinone compounds
05/24/2007WO2007058634A1 Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
05/24/2007WO2007058630A1 Novel bis(amino)-ortho-dicarbaborane cluster compounds
05/24/2007WO2007058628A1 Heteroalkyl linked pyrimidine derivatives
05/24/2007WO2007058627A1 Oxygen linked pyrimidine derivatives
05/24/2007WO2007058626A1 Indazole compounds
05/24/2007WO2007058612A1 Medicament for use in connection with cartilage impairment
05/24/2007WO2007058602A2 Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
05/24/2007WO2007058601A1 Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
05/24/2007WO2007058593A1 Quetiapine in a controlled release formulation
05/24/2007WO2007058583A2 Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
05/24/2007WO2007058582A1 Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
05/24/2007WO2007058581A1 Novel 2-aminopyrimidine derivatives and their use
05/24/2007WO2007058580A1 Novel 2-aminopyrimidinone derivatives and their use
05/24/2007WO2007058523A1 Composition with docosapentaenoic acid
05/24/2007WO2007058504A1 Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same
05/24/2007WO2007058498A1 Compositions for peritoneal dialysis
05/24/2007WO2007058482A1 Novel inhibitors of protein kinase
05/24/2007WO2007058480A1 Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin
05/24/2007WO2007058394A1 Medicinal composition comprising 3-alkoxy-6-allylthiopyridazines for prevention or treatment of cancer of the pancreas
05/24/2007WO2007058392A1 Heterocyclic compound and medicinal application thereof
05/24/2007WO2007058384A1 Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
05/24/2007WO2007058346A1 HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE I
05/24/2007WO2007058338A2 Oxazole compound and pharmaceutical composition
05/24/2007WO2007058336A1 SCREENING METHOD AND IDENTIFICATION METHOD FOR SUBSTANCE CAPABLE OF INHIBITING DEGRANULATION REACTION OR PROSTAGLANDIN D2 PRODUCTION IN MAST CELL THROUGH Rec168, AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE COMPRISING THE SUBSTANCE
05/24/2007WO2007058335A1 Use of tak-475 together with ezetimibe for treating hyperlipidemia
05/24/2007WO2007058323A1 Method for production of nucleic acid homopolymer-bound functional nucleic acid medicine
05/24/2007WO2007058322A1 Basic group-containing compound and use thereof
05/24/2007WO2007058305A1 Process for production of cinnamamide derivative
05/24/2007WO2007058304A1 Salts of cynnamide compound or solvates thereof
05/24/2007WO2007057909A1 Androgen-receptor (ar) ligands for use in the treatment and diagnosis of ar-related pathologies
05/24/2007WO2007057889A2 Succinimide derivatives as ocular hypotensive agents
05/24/2007WO2007057849A2 2,3,4,5-tetrahydroxy-6-sulfooxyhexanoic acid and its metal salts for medical use
05/24/2007WO2007057775A1 Spiropiperidine derivatives
05/24/2007WO2007057767A2 Amino acid derivatives
05/24/2007WO2007057756A2 Isocystene derivatives for the treatment of pain
05/24/2007WO2007057755A1 Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
05/24/2007WO2007057742A2 Novel piperazinone derivatives
05/24/2007WO2007057714A2 Pharmaceutical compositions comprising methotrexate
05/24/2007WO2007057705A1 Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (pbr)